Oppenheimer Forecasts Strong Price Appreciation for Astria Therapeutics (NASDAQ:ATXS) Stock

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) had its target price increased by investment analysts at Oppenheimer from $26.00 to $28.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an "outperform" rating on the biotechnology company's stock. Oppenheimer's target price would suggest a potential upside of 177.50% from the company's current price.

A number of other equities research analysts have also recently weighed in on the company. Wedbush restated an "outperform" rating and issued a $22.00 price target on shares of Astria Therapeutics in a report on Tuesday, August 13th. TD Cowen began coverage on Astria Therapeutics in a report on Monday, July 29th. They issued a "buy" rating and a $35.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Friday, September 27th. Finally, Evercore ISI upgraded Astria Therapeutics to a "strong-buy" rating in a report on Wednesday, August 14th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Astria Therapeutics currently has a consensus rating of "Buy" and an average price target of $25.60.

Astria Therapeutics Price Performance

Shares of ATXS stock traded down $0.52 during trading hours on Thursday, reaching $10.09. 278,942 shares of the company's stock were exchanged, compared to its average volume of 615,468. The company has a market cap of $569.33 million, a P/E ratio of -4.53 and a beta of 0.71. The company's 50 day moving average is $11.46 and its two-hundred day moving average is $10.61. Astria Therapeutics has a 1 year low of $4.26 and a 1 year high of $16.90.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last released its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). As a group, analysts predict that Astria Therapeutics will post -1.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Quest Partners LLC raised its position in Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 3,112 shares during the period. Ameritas Investment Partners Inc. raised its position in Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company's stock valued at $70,000 after purchasing an additional 2,861 shares during the period. SG Americas Securities LLC purchased a new position in Astria Therapeutics in the third quarter valued at about $155,000. Price T Rowe Associates Inc. MD purchased a new position in Astria Therapeutics in the first quarter valued at about $200,000. Finally, Hsbc Holdings PLC purchased a new position in Astria Therapeutics in the second quarter valued at about $171,000. 98.98% of the stock is owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.